Published in Clin Pharmacokinet on January 01, 2001
Diffusion in brain extracellular space. Physiol Rev (2008) 5.34
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis (2008) 2.08
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol (2010) 1.87
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A (2005) 1.29
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol (2008) 1.22
Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci (2013) 1.16
Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm (2013) 1.10
Intranasal treatment of central nervous system dysfunction in humans. Pharm Res (2012) 1.07
Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One (2013) 1.04
Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine (2014) 1.02
Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2011) 1.02
Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci (2008) 1.00
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target (2010) 0.99
Small molecule activators of the Trk receptors for neuroprotection. BMC Neurosci (2008) 0.98
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci (2015) 0.98
Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A (2012) 0.96
Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology (2012) 0.93
Growth factors and stroke. NeuroRx (2006) 0.93
Aberrant insulin signaling in Alzheimer's disease: current knowledge. Front Neurosci (2015) 0.92
Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats. J Neuroendocrinol (2013) 0.88
Adult Mesenchymal Stem Cells: When, Where, and How. Stem Cells Int (2015) 0.87
Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett (2014) 0.86
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurol (2016) 0.86
Nanomedicine for treating spinal cord injury. Nanoscale (2013) 0.84
A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. PLoS One (2014) 0.84
Tetanus toxin C-fragment: the courier and the cure? Toxins (Basel) (2010) 0.84
Upregulation of endogenous neurotrophin levels in the brain by intranasal administration of carnosic acid. J Pharm Sci (2011) 0.84
Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats. Fluids Barriers CNS (2011) 0.83
Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One (2010) 0.83
Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer's disease model rats. PLoS One (2015) 0.83
Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech (2011) 0.82
siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain Injuries. Genes (Basel) (2013) 0.81
Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci (2009) 0.81
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81
Therapeutic time window for the neuroprotective effects of NGF when administered after focal cerebral ischemia. Neurol Sci (2011) 0.81
LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression. Acta Pharmacol Sin (2012) 0.81
Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS. J Neurosci Methods (2015) 0.79
Intranasal drug delivery: a novel approach. Indian J Otolaryngol Head Neck Surg (2009) 0.79
Intranasal delivery of camptothecin-loaded tat-modified nanomicells for treatment of intracranial brain tumors. Pharmaceuticals (Basel) (2012) 0.79
Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence. Neuropeptides (2011) 0.79
Fragment C of tetanus toxin: new insights into its neuronal signaling pathway. Int J Mol Sci (2012) 0.79
Delivery of brain-derived neurotrophic factor via nose-to-brain pathway. Pharm Res (2011) 0.79
Agile delivery of protein therapeutics to CNS. J Control Release (2014) 0.79
Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1. Dialogues Clin Neurosci (2011) 0.78
Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats. PLoS One (2016) 0.78
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice. J Neurol Neurosurg (2015) 0.78
Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial. Transl Psychiatry (2016) 0.78
Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease. Exp Ther Med (2017) 0.78
Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice. Vaccine (2011) 0.77
Strategies for enhanced drug delivery to the central nervous system. Indian J Pharm Sci (2010) 0.77
ERα Signaling Is Required for TrkB-Mediated Hippocampal Neuroprotection in Female Neonatal Mice after Hypoxic Ischemic Encephalopathy(1,2,3). eNeuro (2016) 0.77
Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder. Sci Rep (2016) 0.77
Brain delivery of proteins via their fatty acid and block copolymer modifications. J Drug Target (2013) 0.77
Is tau a suitable therapeutical target in tauopathies? World J Biol Chem (2010) 0.76
Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Med Devices (Auckl) (2015) 0.76
No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. J Clin Psychopharmacol (2013) 0.76
Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil. Pharmazie (2010) 0.76
Restoring nervous system structure and function using tissue engineered living scaffolds. Neural Regen Res (2015) 0.76
Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor. Sci Rep (2016) 0.75
The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain (2017) 0.75
IFNβ Protects Neurons from Damage in a Murine Model of HIV-1 Associated Brain Injury. Sci Rep (2017) 0.75
Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration. Proc Natl Acad Sci U S A (2016) 0.75
In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. Int Sch Res Notices (2014) 0.75
Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study. Drug Des Devel Ther (2015) 0.75
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. J Neurosci Methods (2015) 0.75
Effect of intranasally administered insulin on cerebral blood flow and perfusion; a randomized experiment in young and older adults. Aging (Albany NY) (2017) 0.75
Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm Sin B (2016) 0.75
Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model. J Neurosci Methods (2014) 0.75
Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J (2016) 0.75
Effect of exogenous glial cell-derived neurotrophic factor on development of the enteric nervous system in the rectal end of fetal rats with anorectal malformations. Pediatr Surg Int (2013) 0.75
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience (2004) 2.86
Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology (1990) 2.36
Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging (2005) 2.15
Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer's disease. Neurology (2000) 1.95
Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res (1995) 1.65
Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci (2001) 1.42
Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol (1995) 1.36
Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol (2004) 1.29
Pick's disease versus Alzheimer's disease: a comparison of clinical characteristics. Neurology (1993) 1.20
Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett (2001) 1.18
Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience (2008) 1.14
Binding of acetyl-CoA to chicken liver pyruvate carboxylase. J Biol Chem (1977) 1.05
Structural properties of pyruvate carboxylases from chicken liver and other sources. Proc Natl Acad Sci U S A (1975) 1.02
Transforming growth factor beta in Alzheimer's disease. Clin Diagn Lab Immunol (1994) 0.96
Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord (1992) 0.95
Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol (1994) 0.92
Risk factors in Alzheimer's disease: a clinicopathologic study. Neurology (1992) 0.91
Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer's brain. Lancet (1985) 0.90
Validation of the NINCDS-ADRDA criteria regarding gait in the clinical diagnosis of Alzheimer disease. A clinicopathologic study. Alzheimer Dis Assoc Disord (1995) 0.90
Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest (1997) 0.89
Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry (1997) 0.88
Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. Mol Chem Neuropathol (1995) 0.88
Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids (1998) 0.87
Glial fibrillary acidic protein and Alzheimer's disease. Neurochem Res (1985) 0.87
Posterior cortical atrophy: neuropathological correlations. Arch Neurol (1996) 0.86
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res (2012) 0.86
Altered aspartate in Alzheimer neurofibrillary tangles. Neurochem Res (1992) 0.85
Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles. Neurology (1987) 0.85
The use of the ultracentrifuge to determine the catalytically competent forms of enzymes with more than one oligomeric structure. Multiple reacting forms of pyruvate carboxylase from chicken and rat liver. J Biol Chem (1978) 0.83
Human brain tubulin purification: decrease in soluble tubulin with age. Neurochem Res (1985) 0.83
Catecholamine-sensitive guanylate cyclase from human caudate nucleus. J Neurochem (1980) 0.81
Effect of stimulus on the chemical composition of human tears. Am J Ophthalmol (1981) 0.81
Racemized D-aspartate in Alzheimer neurofibrillary tangles. Brain Res Bull (1992) 0.80
Retracted Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis. Neuroscience (2008) 0.80
Status selective white flight and central city population change: a comparative analysis. J Reg Sci (1980) 0.79
Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Brain Res (1997) 0.79
Seasonal distribution of births in Alzheimer's disease. Int Psychogeriatr (1991) 0.79
Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve media. Brain Res (1999) 0.78
Effect of dopamine on activation of rat striatal adenylate cyclase by free Mg2+ and guanyl nucleotides. J Neurochem (1980) 0.77
GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy. Arch Neurol (1990) 0.77
Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. J Mol Neurosci (1998) 0.77
Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci (2000) 0.77
Neuropathologically confirmed Alzheimer's disease: clinical diagnoses in 394 cases. J Geriatr Psychiatry Neurol (1991) 0.77
A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. Biol Psychiatry (1982) 0.77
Manganese- and magnesium-dependent activities of soluble and particulate guanylate cyclase from sheep kidney outer medulla. J Biol Chem (1977) 0.77
Immunogold labeling of Alzheimer paired helical filaments with ganglioside MAB A2B5. Alzheimer Dis Assoc Disord (1990) 0.76
Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. J Neural Transm (Vienna) (1999) 0.76
Black migration to the South reaches record highs in 1990s. Popul Today (1998) 0.76
Polyethylene glycol interferes with protein molecular weight determinations by gel filtration. Anal Biochem (1984) 0.76
D-aspartate in human brain. J Neurochem (1987) 0.76
A clinicopathological study of CT scans in Alzheimer's disease. J Am Geriatr Soc (1992) 0.76
The tears of the physician. JAMA (1990) 0.75
The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol (1994) 0.75
Deletion in the prion protein gene in a demented patient. Hum Mol Genet (1992) 0.75
Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study. Acta Neuropathol (2000) 0.75
Ionic regulation of antagonist binding to the human muscarinic cholinergic receptor of caudate nucleus. J Psychiatr Res (1984) 0.75
The re-emergence of core region growth: a return to the metropolis? Int Reg Sci Rev (1988) 0.75
The changing impact of white migration on the population compositions of origin and destination metropolitan areas. Demography (1979) 0.75
South-North immigrants' settlement and opportunity structures in the U.S. Asian Pac Migr J (1998) 0.75
Impacts of low-skilled immigration on the internal migration of the U.S.-born low-skilled Americans in the United States: an assessment in a multivariate context. Jinkogaku Kenkyu (1998) 0.75
White flight and central-city loss: application of an analytic migration framework. Environ Plan A (1979) 0.75
Changing families and changing mobility: their impact on the central city. Demography (1982) 0.75
Postmortem stability of dopamine-sensitive adenylate cyclase, guanylate cyclase, ATPase, and GTPase in rat striatum. J Neurochem (1981) 0.75
Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms. J Neuroimmunol (1994) 0.75
Metropolitan America: beyond the transition. Popul Bull (1990) 0.75
Inhibition of antagonist binding to human brain muscarinic receptor by vanadium compounds. Recept Signal Transduct (1997) 0.75
Lifecourse migration and redistribution of the elderly across U.S. regions and metropolitan areas. Econ Outlook USA (1986) 0.75
Are two Americas emerging? Popul Today (1991) 0.75
Stimulation of guanylate cyclase by EDTA and other chelating agents. Biochim Biophys Acta (1981) 0.75
Immigration impacts on internal migration of the poor: 1990 census evidence for U.S. states. Int J Popul Geogr (1995) 0.75
Changing urban populations: regional restructuring, racial polarization, and poverty concentration. Cityscape (1995) 0.75
Mover destination selectivity and the changing suburbanization of metropolitan whites and blacks. Demography (1985) 0.75
Population movement and city-suburb redistribution: an analytic framework. Demography (1978) 0.75
A multiregional population-projection framework that incorporates both migration and residential mobility streams: application to metropolitan city-suburb redistribution. Environ Plan A (1983) 0.75
Clinical characteristics of chronic Creutzfeldt-Jakob disease. J Geriatr Psychiatry Neurol (1995) 0.75
Multiple sclerosis dementia. Neurology (1992) 0.75